
Isomorphic Labs raises $5B Series C in 2026
Isomorphic Labs, the AI drug-discovery company, raised a $5B Series C to push its drug candidates toward clinical trials.
Daily Digest
Daily Digest
Pomegra Startups
Deep tech startup news: biotech, robotics, hardware, energy, defence, and security companies - the capital-intensive bets with long horizons and hard science behind them.

Isomorphic Labs, the AI drug-discovery company, raised a $5B Series C to push its drug candidates toward clinical trials.

Treat (Finland) raised €3M to fix inefficiencies in private healthcare operations.

Israeli-founded AI cybersecurity startup Corma raised a $125M Series A at a $1B valuation, led by NEA, just three months after emerging from stealth.

French biotech Orakl Oncology raised a $34M Series A for AI-driven predictive oncology using patient-derived tumor models.

Israeli AI-agent security startup Bay emerged from stealth with $50M ($37M Series A led by Battery Ventures) to monitor and control autonomous AI agents.

Bay (US) emerged from stealth with $50M in seed and Series A funding for an AI agent security and management platform used by Fortune 100 companies.

Switchpoint Bio (Finland/UK) emerged from stealth with a $5.3M pre-seed to study why patients respond differently to drugs.

Duet (US) raised a $15M Series A for its network of nurse practitioner-owned primary care practices.

Biomatter (Lithuania) raised $18M from Astanor and UVC Partners to build an enzyme lab in Vilnius.

Neurosterix (Switzerland/US) raised $105M to advance experimental treatments for schizophrenia and other neurological conditions.

Brava Security (US) emerged from stealth with $15M in funding.

Mosaic (US) emerged from stealth with $47M to build intelligent surgical machines that treat the body from the inside.

CrowdStrike is reportedly in advanced talks to acquire Israeli AI data-security startup Orion for about $500M. The deal is unconfirmed.

Neobe (UK) raised €6.1M to engineer bacteria that break down the barriers protecting tumours.

Crowd Threat (UK) raised £1M to expand its global threat-intelligence platform.

Anaheim Bio (Netherlands) raised €40M to develop a treatment for calcium pyrophosphate deposition disease.

Sentra (Israel), a data security company that protects corporate data from AI agents, raised a $150M Series C led by Capital One Ventures.

Laza Medical raised up to $160M in a Series B led by GE HealthCare for AI-powered robotic imaging in cardiac catheterization.

Upwind raised $400M at a $3.8B valuation for cloud security and AI defense.

OSSTEC (Imperial College spinout) raised $8M for the US launch of its joint replacements.

Biograil (Copenhagen) raised €20M to develop an oral drug-delivery device as an alternative to injections.

bit.bio (Cambridge, UK), a human cell programming company, closed a $25M Series D for lab-grown human cell models.

Brava Security (Israel/US) came out of stealth with a $15M seed from F2 Venture Capital and Pitango for an AI platform that tests whether security tools detect attacks.

CrowdStrike agreed to acquire Fiddler AI (AI agent observability) for about $400M and Dreadnode (AI security testing) for about $95M.

Blue Arbor Technologies raised a $10.5M Series A.

Infisical raised a $40M Series B at a $600M valuation for credential and secrets-management security.

Impress (Spain), a digital orthodontics network, raised €40M to expand across Europe.

Transpharmation (UK) acquired OrganoTherapeutics, a Luxembourg startup building patient-derived brain organoid models.

Mave (Israel), a cybersecurity startup, raised a $28M Series A led by Red Dot Capital Partners.

Samplix, a Danish biotech, secured €25M in the first close of a financing round.
Deep tech companies commercialise hard science rather than software alone: a new battery chemistry, a reactor design, a drug candidate, a robot that works outside a lab. What they share is a long, expensive path between the first cheque and the first revenue, because the risk being funded is whether the technology works at all, not whether customers want it. That changes how their rounds read - a large raise can mean a company is years from a product, not close to one.
That profile also makes deep tech the segment where private capital matters most. Public markets rarely fund a decade of pre-revenue research, so the important valuation events happen privately, and the eventual IPO or acquisition prices work that was already done. Coverage here groups biotech, robotics, hardware, energy, defence, and security together because they behave alike as investments, even when the science does not.
Because the risk being funded is technical. Clinical trials, reactor licensing, and hardware manufacturing all have timelines set by physics and regulators rather than by product iteration, so a decade between founding and exit is normal rather than a warning sign.
The failure modes differ. Deep tech can fail outright if the science does not work, but a company that succeeds often has durable advantages that are hard to copy. Software fails less absolutely and is competed away faster. This is educational context, not investment advice.